Revorf

What Revorf does

Revorf, operationally known as AOI Biosciences, is a privately held Japanese medical-technology company founded in November 2019, headquartered in Ibaraki, Osaka Prefecture, with a second office embedded within Osaka University's Institute of Microbial Disease Research in Suita. The company's business is built around its proprietary "Neo-self Theory," a novel mechanistic framework explaining the root causes of autoimmune diseases, which serves as the foundational platform for both its diagnostic and therapeutic programs. Its primary commercialized product is the β2GPI Neo-self Antibody Test, a clinical diagnostic for infertility and recurrent miscarriage operated through a registered medical testing facility (Osaka Prefecture permit No. 179) in Japan.

Revorf operates two principal revenue streams. The first is clinical diagnostic services delivered directly to infertility and recurrent miscarriage patients through its registered testing facility, targeting autoimmune-related reproductive conditions that lack widely available diagnostic solutions. The second is a professional-services revenue line supporting pharmaceutical companies in drug discovery and biomarker development, including allosteric drug discovery enabled by a strategic partnership with Toshiba using the SQBM+™ quantum-inspired optimization solution. The company serves two distinct customer segments: end-patient consumers seeking novel reproductive diagnostics (primary segment) and pharmaceutical companies seeking computational biology and biomarker-development support (primary segment).

The company is pursuing a third, longer-dimension leg of growth: development of a next-generation antibody-drug conjugate (ADC) therapeutic platform targeting autoimmune diseases with reduced side-effect profiles, recognized by the Ikeda Shinhoku Bank Innovation R&D Excellence Award in March 2026. Revorf has raised approximately $44.9 million across a 2021 seed and a 2024 round led by a strategic-corporate syndicate (Sumitomo Corporation, Toshiba Digital Solutions, ZACROS Japan, Beyond Next, Bio Engineering Capital, Nippon Venture Capital, UntroD Capital). The company is led by physician-founder Shinichi Sueda (Representative Director) with CFO/CSO Shuhei Kurioka, and a scientific advisory board drawn from Teine Keijinkai Hospital, the University of Tokyo, Osaka University, and Teikyo University.

Name

Revorf

Legal name

AOI Biosciences株式会社

Website

https://revorf.jp

Company type

Private

Founded year

2019

Operating status

Operating

Short description

Revorf (AOI Biosciences) is a Japanese biotech founded in 2019 that develops autoimmune disease diagnostics and drug discovery support services built on its proprietary Neo-self Theory, serving infertility patients through a registered clinical testing facility and pharmaceutical companies via computational biology partnerships.

Ownership category

akta.pro rank

Product category

Medical Diagnostics & Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413), Scientific Research and Development Services (5417)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD)

akta.pro secondary industries

Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE), Real-World Evidence (RWE) & HEOR for Development (HLAIALAI)

Keywords

• Autoimmune diagnostics
• Drug discovery services
• Biomarker development
• Infertility antibody testing
• Allosteric drug discovery

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. β2GPI Neo-self Antibody Testing Services: Clinical testing services for infertility/miscarriage diagnosis using the proprietary Neo-self antibody detection technology. Operated as a registered medical testing facility.
2. Diagnostic Development Support: Supporting pharmaceutical companies in developing novel diagnostics based on Neo-self theory technology platform
3. Drug Discovery Support Services: Providing computational biology and biomarker development services to pharmaceutical companies, including quantum-inspired optimization for allosteric drug discovery

Distribution channels1 record

Marketing channels2 records

Core offering

Revorf develops and operates a Neo-self theory based diagnostics and drug discovery platform. Its primary commercial offering is a β2GPI Neo-self antibody clinical testing service for infertility and recurrent miscarriage diagnosis, delivered through a registered medical testing facility in Ibaraki, Japan. For pharmaceutical clients, it provides drug discovery support services, including biomarker development and quantum-inspired allosteric drug discovery through a collaboration with Toshiba Digital Solutions using SQBM+™.

Product overview

AOI Biosciences offers a portfolio of bioscience products and services based on two core technology platforms: the neo-self theory (a novel mechanism explaining the root causes of autoimmune diseases) and biological information analysis technology. The company provides a β2GPI Neo-Self Antibody Test as a diagnostic product for infertility/sterility, along with drug discovery and discovery support services leveraging computational processing and quantum-inspired optimization solutions.

Differentiator

Problem solved

Functional benefit

Brands

• ネオセルフ抗体検査 (Neo-self Antibody Test): β2GPI Neo-self antibody test for infertility diagnosis

Products and services

• β2GPI Neo-self Antibody Testing (β2GPIネオセルフ抗体検査)

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Toshiba (株式会社東芝)coreTechnology or IntegrationCollaboration utilizing Toshiba's quantum-inspired optimization solution (SQBM+™) for allosteric drug discovery. AOI Biosciences leverages this technology to support pharmaceutical company drug discovery programs through computational analysis of biological information and biomarker development.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Direct peers

• Sysmex Corporation: Japanese in-vitro diagnostics leader that develops and markets clinical laboratory tests and diagnostic reagents globally. Directly comparable to AOI's clinical diagnostic testing business, particularly in autoimmune and reproductive health indications.
• Eiken Chemical Co., Ltd. Japanese IVD manufacturer specializing in clinical chemistry, immunoassay, and molecular diagnostic reagents. Comparable in producing diagnostic test substances and reagents for clinical laboratory use, including autoimmune-related assays.
• Kyowa Kirin Co., Ltd. Japanese specialty pharmaceutical company focused on autoimmune and immunology therapeutics. Comparable as a Japan-based drug developer in the same autoimmune disease indication space that AOI's Neo-self ADC platform targets.

Broad incumbents

• H.U. Group Holdings: Major Japanese clinical laboratory testing and in-vitro diagnostics conglomerate operating SRL and other testing facilities. Comparable as a large-scale clinical testing and diagnostics services incumbent in Japan.
• BML, Inc. Japanese clinical reference laboratory providing routine and specialized diagnostic testing services to hospitals and clinics. Comparable to AOI's registered medical testing facility operations and clinical service model.
• Ono Pharmaceutical Co., Ltd. Major Japanese pharmaceutical company with significant autoimmune and immunology franchises. Comparable as a larger Japanese pharma that could be a customer or competitor in autoimmune therapeutic development.
• Astellas Pharma Inc. Large Japanese pharmaceutical company with a growing autoimmune and biologics portfolio including ADC development. Comparable as a strategic pharma partner or acquirer with overlapping therapeutic development interests.
• Charles River Laboratories: Global contract research organization providing drug discovery and development services including biomarker discovery. Comparable to AOI's drug discovery support services and biomarker development offerings for pharma clients.
• IQVIA Holdings: Global clinical research and drug discovery services provider with deep pharma partnerships. Comparable as a much larger scale drug discovery support and biomarker service provider that AOI competes against for pharma R&D budgets.

Emerging players

• Eurofins Scientific: Global bioanalytical testing and contract research services group with strong biomarker and clinical diagnostics capabilities. Comparable as a CRO-style competitor for bioanalytical and biomarker discovery services.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds2 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Revorf